Premium
Bortezomib: a new therapeutic option for POEMS syndrome
Author(s) -
Kaygusuz Isik,
Tezcan Hakan,
Cetiner Mustafa,
Kocakaya Ozan,
Uzay Ant,
Bayik Mahmut
Publication year - 2010
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.2009.01341.x
Subject(s) - poems syndrome , bortezomib , polyneuropathy , medicine , pathogenesis , proinflammatory cytokine , disease , surgery , inflammation , multiple myeloma
Objective: POEMS syndrome with its classical five findings ( P olyneuropathy, O rganomegaly, E ndocrinopathy, M protein, and S kin changes) is a rare multisystem disease. Proinflammatory and proangiogenic cytokines play important roles in its pathogenesis. Treatment options are still debated. Methods: We present a 65‐year‐old man with POEMS syndrome who was successfully treated with bortezomib. Results: After seven cycles of this protocol, serum M protein level declined to normal range, and near‐to‐complete remission was achieved. His symptoms of polyneuropathy improved dramatically. Conclusion: Bortezomib may be an effective and safe therapeutic option for patients with POEMS syndrome.